Morgan Stanley issued an Underweight rating on Cipla, which is driving US commercialization.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley issued an Underweight rating on Cipla, which is driving US commercialization.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Morgan Stanley
U.S. investment bank
-
Cipla
Indian multi-national pharmaceutical and biotechnology company
Nothing else this week.
Related events
- Morgan Stanley lowered its rating for CAE Inc from equal weight to underweight on August 27, 2026.
- Morgan Stanley reiterated an overweight rating and Citigroup upgraded its rating on Cadence Design Systems.
- Morgan Stanley analyst provides Overweight rating for SpaceX.
- Morgan Stanley issued an underweight rating on Hess Midstream Partners LP.
- Morgan Stanley set an underweight rating and Raymond James Financial reiterated an outperform rating for Northern Oil and Gas, Inc.